COVID-19 transmission graph

Coronavirus: WHO declares COVID 19 a pandemic. Prevention | FAQs | COVID-19 portal

URGENT:COVID prophylaxis | Vitamin D | Latest research | NIH | CDC | Worldometer

NB:Did you know one coronavirus patient can infect 59,000 others if nothing is done? Dietary cholesterol may not raise cardiovascular risk! Ketogenic diet

Neuromyelitis optica

From WikiMD
Jump to navigation Jump to search

Neuromyelitis optica (NMO), is a heterogeneous condition consisting of the inflammation and demyelination of the optic nerve (optic neuritis) and the spinal cord (myelitis). It can be monophasic or recurrent. Currently at least three different kinds are proposed based on the presence of autoantibodies thought to produce the disease: anti-AQP4, anti-MOG and anti-NF. All the cases are considered autoimmune diseases.

Spinal cord lesions lead to varying degrees of weakness or paralysis in the legs or arms, loss of sensation (including blindness),[1] and/or bladder and bowel dysfunction.[2]

Devic's disease is now studied along a collection of similar diseases called "Neuromyelitis optica spectrum diseases".[3]

Signs and symptoms

The main symptoms of Devic's disease are loss of vision and spinal cord function. Optic neuritis may manifest as visual impairment with decreased visual acuity, although visual field defects, or loss of color vision may occur in isolation or prior to formal loss of acuity. Spinal cord dysfunction can lead to muscle weakness, reduced sensation, or loss of bladder and bowel control.[4] The typical patient has an acute and severe spastic weakness of the legs (paraparesis) or all four limbs (quadriparesis) with sensory signs, often accompanied by loss of bladder control.Script error: No such module "Category handler".Script error: No such module "Category handler".[citation needed]

Causes

Illustration of the four different types of glial cells found in the central nervous system: ependymal cells, astrocytes, microglial cells, and oligodendrocytes

Devic's disease was associated in the past with many systemic diseases, based on anecdotal evidence. The discovery of NMO-IgG (anti-AQP4) has opened a new way into the research for the causes. Currently three principal causes are accepted:

  • A first subset of patients is anti-AQP4+. In them, the cause of the neuromyelitis optica (understood as the syndrome) is an autoimmune aquaporin-4 channelopathy, due to these specific autoantibodies.[5] In these cases, astrocytes are the victims of the autoimmune attack.
  • In a third subset of patients, NMO is due to the presence of anti-neurofascin (anti-NF) auto-antibodies which damage the Ranvier nodes of the neurones.[7] These antibodies are more related to the peripheral nervous demyelination, but they were also found in NMO.[8]

Rarely, it has been reported that some courses of anti-NMDAR are consistent with NMO[9]. It is not excluded the possibility that new kinds of autoantibodies could appear in NMO.

anti-AQP4+ variants

In the AQP4+ cases, these auto-antibodies target the protein aquaporin 4 in the cell membranes of astrocytes which acts as a channel for the transport of water across the cell membrane.[2] In any case, the anti-AQP4 generation is produced mainly intrathecally.[10]

Aquaporin 4 is found in the astrocytes that surround the blood–brain barrier (BBB), a system responsible for preventing substances in the blood from crossing into the brain. The blood–brain barrier is weakened in Devic's disease, but it is currently unknown how the auto-antibodies cross the BBB. Some reports point to the metalloproteinase-2 and interleukin-6 as culprits for the BBB failure.[11] There is broad consensus that AQP4/NMO-IgG initially enters the brain via BBB-deficient sites such as area postrema, where access to CSF occurs.[12]

There are "normal appearing areas" in NMO but compared to patients with MS, NAWM damage is less extensive.[13]

Most research into the pathology of Devic's disease has focused on the spinal cord. The damage can range from inflammatory demyelination to necrotic damage of the white and grey matters. The inflammatory lesions in Devic's disease have been classified as type II lesions (complement-mediated demyelinization), but they differ from MS pattern II lesions in their prominent perivascular distribution. Therefore, the pattern of inflammation is often quite distinct from that seen in MS.[2][14]

About the presence of anti-AQP4 autoantibodies, some researchers have pointed out that some other cases could be paraneoplastic.[15] It seems also clear that lupus can produce NMO-IgG autoantibodies sometimes, leading to some cases of lupus-derived NMO.[16]

AQP4+ NMO is the most common and is considered an autoimmune astrocytopathy[17] or autoimmune astrocytic channelopathy) in which a person's own immune system attacks the astrocytes of the optic nerves and spinal cord.[18]

In Anti-AQP4 positive variants, CNS astrocytes, which are the basis for the glymphatic system[19] are the target of the autoimmune attack. NMO-IgG-negative cases are less understood. It seems currently that astrocytes are spared in these IgG negative cases.[20]

anti-MOG+ variants

Currently, the second most documented auto-antibody in NMO is anti-MOG autoantibody.

MOG antibodies are currently considered mostly absent in similar diseases like multiple sclerosis.[21] Therefore, it can be said that anti-MOG is a group contained inside AQP-Negative NMO.[22]

Together with the anti-AQP4 they form the wider part of the NMO spectrum. They classify the NMO cases in four classes, according to the presence or absence of any of these two main auto-antibodies.[23]

The clinical course and the response to therapy is different for these groups, showing a better prognosis for those in the NMO-Ab(−)/MOG-Ab(−) group, and a worse prognosis for those in the NMO-Ab(+)/MOG-Ab(+) group.[23] The MOG-related neuromyelitis optica can be radiologically identified by the conus involvement. Myelin-oligodendrocyte glycoprotein antibody–positive patients were more likely to have conus involvement on spinal magnetic resonance imaging.[24]

Anti-Neurofascin variants

NF auto antibodies can also appear in NMO cases.[7] These antibodies are more related to the peripheral nervous demyelination, but they were also found in NMO.[25]

Diagnosis

The Mayo Clinic proposed a revised set of criteria for diagnosis of Devic's disease in 2006. Those new guidelines require two absolute criteria plus at least two of three supportive criteria.[26] In 2015 a new review was published by an international panel[3] refining the previous clinical case definition but leaving the main criteria unmodified:

Absolute criteria:

  1. Optic neuritis
  2. Acute myelitis

Supportive criteria:

  1. Brain MRI not meeting criteria for MS at disease onset
  2. Spinal cord MRI with continuous T2-weighted signal abnormality extending over three or more vertebral segments, indicating a relatively large lesion in the spinal cord
  3. NMO-IgG seropositive status (The NMO-IgG test checks the existence of antibodies against the aquaporin 4 antigen.)

Neuromyelitis optica spectrum disorders

Since the discovery of AQP4 autoantibody, it has been found that it appears also in patients with NMO-like symptoms that do not fulfill the clinical requirements to be diagnosed NMO (Recurrent and simultaneous optic nerve and spinal cord inflammation).[27]

The term NMOSD (NMO Spectrum Disorders) has been designed to allow incorporation of cases associated a non-AQP4 biomarkers.[3] Therefore, it includes all the clinical variants due to anti-AQP4 plus other non-related but clinically similar syndromes like antiMOG associated encephalomyelitis. Some cases with MOG+ and AQP4+ antibodies have been found.[3]

The collection of these condition has been named "neuromyelitis optica spectrum disorders" (NMSD) and they are expected to respond to the same treatments as standard NMO.[28] Some authors propose to use the name "autoimmune aquaporin-4 channelopathy" for these diseases,[5] while others prefer a more generic term "AQP4-astrocytopathy" that includes also problems in AQP4 with a non-autoimmune origin.[29]

Variants

After the development of the NMO-IgG test, the spectrum of disorders comprising Devic's disease was expanded. The spectrum is now believed to consist of:

Whether Devic's disease is a distinct disease or part of the wide spectrum of multiple sclerosis is debated.[34] Devic's disease differs in that it usually has more severe sequelae after an acute episode than standard MS, MS infrequently presents as transverse myelitis, and oligoclonal bands in the CSF, as well as white matter lesions on brain MRI, are uncommon in Devic's disease, but occur in over 90% of MS patients.[35]

Recently, AQP4 has been found to distinguish standard multiple sclerosis from neuromyelitis optica, but as MS is a heterogeneous condition,[36] and some MS cases are reported to be Kir4.1 channelopathies[37] (autoimmunity against the potassium channels) it is still possible to consider NMO as part of the MS spectrum. Besides, some NMO-AQP(−) variants are not astrocytopathic, but demyelinating.[38]

Tumefactive lesions

Tumefactive demyelinating lesions in NMO are not usual, but they have been reported to appear in several cases mistakenly treated with interferon beta.[39]

Differential diagnosis

AQP4-Ab-negative NMO presents problems for diagnosis. The behavior of the oligoclonal bands respect MSScript error: No such module "Category handler".Script error: No such module "Category handler".[clarification needed] can help to establish a more accurate diagnosis. Oligoclonal bands in NMO are rare and they tend to disappear after the attacks, while in MS they are nearly always present and persistent.[40]

It is important to notice for differential diagnosis that, though uncommon, it is possible to have longitudinal lesions in MS.[41]

Other problem for diagnosis is that AQP4ab in MOGab levels can be too low to be detected. Some additional biomarkers have been proposed.[42][43]

Treatment

Chemical structure of methylprednisolone, which is used to treat attacks

Currently, there is no cure for Devic's disease, but symptoms can be treated. Some patients recover, but many are left with impairment of vision and limbs, which can be severe.

Attacks

Attacks are treated with short courses of high dosage intravenous corticosteroids such as methylprednisolone IV.

Plasmapheresis can be an effective treatment[31] when attacks progress or do not respond to corticosteroid treatment. Clinical trials for these treatments contain very small numbers, and most are uncontrolled, though some report high success percentage.[44]

Secondary prevention

Treatment in order to prevent relapses within neuromyelitis optica is generally employed, though the exact duration of prophylaxis is still debated.[45] In 2019, eculizumab became the first and only medication to be approved by the FDA for the treatment of neuromyelitis optica spectrum disorder in adults who are AQP4 antibody positive.[46] Other immunosuppressant treatments that are used include azathioprine (Imuran) plus prednisone, mycophenolate mofetil plus prednisone, mitoxantrone, intravenous immunoglobulin (IVIG), and cyclophosphamide.[31][47]

B-cell depletion, which indirectly reduces the antibody levels, has been tried[48] with the monoclonal antibody rituximab, showing good results.[49]

Several other disease modifying therapies are being tried. In 2007, Devic's disease was reported to be responsive to glatiramer acetate[50] and to low-dose corticosteroids.[51] Use of Mycophenolate mofetil is also currently under research.[52]

Hematopoietic stem cell transplantation (HSCT) is sometimes used in severe cases of NMO. Currently available data suggest that this procedure can reduce inflammatory activity in the short term, but a clear majority of the patients will relapse within 5 years.[53]

Prognosis

Normally, some measure of improvement appears in a few weeks, but residual signs and disability may persist, sometimes severely.

The disease can be monophasic, i.e. a single episode with permanent remission. However, at least 85% of patients have a relapsing form of the disease with repeated attacks of transverse myelitis and/or optic neuritis. In patients with the monophasic form, the transverse myelitis and optic neuritis occur simultaneously or within days of each other. On the other hand, patients with the relapsing form are more likely to have weeks or months between the initial attacks, and to have better motor recovery after the initial transverse myelitis event. Relapses usually occur early, with about 55% of patients having a relapse in the first year and 90% in the first five years.[2]

It is possible that the relapsing form is related to the antiAQP4+ seropositive status and the monophasic form related to its absence[54] Unlike multiple sclerosis, Devic's disease rarely has a secondary progressive phase in which patients have increasing neurologic decline between attacks without remission. Instead, disabilities arise from the acute attacks.[2]

Approximately 20% of patients with monophasic Devic's disease have permanent visual loss, and 30% have permanent paralysis in one or both legs. Among patients with relapsing Devic's disease, 50% have paralysis or blindness within five years. In some patients (33% in one study), transverse myelitis in the cervical spinal cord resulted in respiratory failure and subsequent death. However, the spectrum of Devic's disease has widened due to improved diagnostic criteria, and the options for treatment have improved; as a result, researchers believe these estimates will be lowered.[2]

Epidemiology

The prevalence and incidence of Devic's disease has not been established, partly because the disease is underrecognized and often confused with MS.[2] Devic's disease is more common in women than men, with women comprising over two-thirds of patients and more than 80% of those with the relapsing form of the disease.[2]

A retrospective study found that prevalence of NMOsd was 1.5% inside a random sample of neurological patients, with a MS:NMOsd ratio of 42.7. Among 13 NMOsd patients, 77% had long spinal cord lesions, 38% had severe optic neuritis and 23% had brain or brainstem lesions. Only 56% had clinically definite NMO at follow-up.[55]

According to the Walton Centre in England, "NMO seems to be present across the world unlike MS, which has a higher incidence in temperate climates and white races. Africans and Asians especially in Far East may have a higher risk of NMO, although the exact incidence of this disease is unknown, making specific conclusions difficult". Although many people who have Devic's disease were initially misdiagnosed with MS, 35% of African Americans are often misdiagnosed with MS when they really have NMO.Script error: No such module "Category handler".Script error: No such module "Category handler".[citation needed]

Devic's disease is more common in Asians than Caucasians. In fact, Asian optic-spinal MS (which constitutes 30% of the cases of MS in Japan) has been suggested to be identical to Devic's disease (differences between optic-spinal and classic MS in Japanese patients). In the indigenous populations of tropical and subtropical regions, MS is rare, but when it appears, it often takes the form of optic-spinal MS.[56]

The majority of Devic's disease patients have no affected relatives, and it is generally regarded as a nonfamilial condition.[2]

History

First reports on an association of spinal cord and optic nerve disorders appeared in the early 19th century.[57] However, only an 1870 report by Sir Thomas Clifford Allbutt created sustained interest of neurologists and ophthalmologists in this rare syndrome.[58] In 1894, Eugène Devic and his PhD student Fernand Gault described 16 patients who had lost vision in one or both eyes and within weeks developed severe spastic weakness of the limbs, loss of sensation and often bladder control. They recognized these symptoms were the result of inflammation of the optic nerve and spinal cord, respectively.[57][59][60]

Similar instances of optic neuritis and myelitis were reported, and many believed it constituted a distinct clinical entity. However, some patients had pathology in other parts of the brain, a feature which was more suggestive of acute disseminated encephalomyelitis or MS.Script error: No such module "Category handler".Script error: No such module "Category handler".[citation needed]

In 2002, Mayo Clinic researchers identified an humoral mechanism, targeting a perivascular protein, as the culprit for NMO [14] and in 2004 an unknown specific autoantibody was found.[61] In 2005 they identified the aquaporin 4 protein as the target of the disease, and developed a test to aid in the diagnosis of Devic's disease by detection of an antibody, NMO-IgG, in the blood.[19] Some patients with NMO may be seronegative for NMO-IgG, whilst some patients with NMO-IgG may still not fulfill clinical criteria for NMO thus serological testing is now an important part of the diagnostic procedure and seropositive and seronegative cases are described in a manner similar to myasthenia gravis. According to the Mayo Clinic report, this was the first time a molecular target had been identified for a type of demyelinating inflammatory disease.[62]

Research directions

Since the discovery of AQP-4 involvement, some research studies have focused on targeted treatment aimed at anti-aquaporin 4 antibodies. The most established method for antibody removal is plasmapheresis. A number of drugs are being studied: aquaporumab (non-pathogenic antibody blocker of AQP4-IgG binding), sivelestat (neutrophil elastase inhibitor), and eculizumab (complement inhibitor).[63]

There is little research into the primary causes of the Anti-AQP4 auto-antibodies. It has been noticed that some cases could be paraneoplastic.[15]

In addition, several NMO variants have been discovered with antibodies other than those for AQP4, turning NMO into a heterogeneous disease. Six different patterns of damage have been reported in NMO, raising the possibility of six different types of auto-antibodies. As of 2019 only three of them are known.[64]

Research into new auto-antibodies

A new auto-antibody (GFAP) was found in 2016 in transverse myelitis (LETM) and atypical NMO, leading to the concept of Autoimmune GFAP Astrocytopathy.[65]

Other auto-antibody under research is flotillin. It has been found in seronegative NMO and some MS patients[66]

Finally, other proteins under study are Connexin 43 and anti-AQP1 though, as of 2015, there are only initial reports about the involvement of these proteins[27][29]

The group AQP+/MOG+ is very small and it can be considered a coincidence of two independent problems in the same person. Assuming these cases could be verified, currently five different kinds of NMO are being considered:

  • NMO derived from an autoimmune channelopathy (AQP4-Ab+), around 80% of the cases
  • NMO derived from an antiMOG associated encephalomyelitis,[6] around 10% of the cases
  • Connexin-43 NMO
  • Aquaporin-1 associated NMO
  • Idiopatic NMO, defined by the absence of all previous antibodies

Notable patients

See also

References

  1. 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 2.8 Script error: No such module "Citation/CS1".
  2. 3.0 3.1 3.2 3.3 Script error: No such module "Citation/CS1".
  3. Script error: No such module "citation/CS1".
  4. 5.0 5.1 Script error: No such module "Citation/CS1".
  5. 6.0 6.1 Script error: No such module "Citation/CS1".
  6. 7.0 7.1 Jun-ichi Kira, Ryo Yamasaki, Hidenori Ogata, Anti-neurofascin autoantibody and demyelination, Dec 2018, Neurochemistry International, doi: https://doi.org/10.1016/j.neuint.2018.12.011
  7. Kun Jia et al., Anti-neurofascin-155 antibody-positive neuromyelitis optica spectrum disorders, Journal of Neurological Sciences, January 16, 2019, DOI: https://doi.org/10.1016/j.jns.2019.01.024
  8. M.C. Kruer, T.K. Koch, D.N. Bourdette, D. Chabas, E. Waubant, S. Mueller, M.A. Moscarello, J. Dalmau, R.L. Woltjer, G. Adamus, NMDA RECEPTOR ENCEPHALITIS MIMICKING SERONEGATIVE NEUROMYELITIS OPTICA, Neurology, May 04, 2010; 74 (18) Clinical/Scientific Notes, DOI: https://doi.org/10.1212/WNL.0b013e3181dc1a7f
  9. Script error: No such module "Citation/CS1".
  10. Script error: No such module "Citation/CS1".
  11. Script error: No such module "Citation/CS1".
  12. Script error: No such module "Citation/CS1".
  13. 14.0 14.1 Script error: No such module "Citation/CS1".
  14. 15.0 15.1 Script error: No such module "Citation/CS1".
  15. Script error: No such module "Citation/CS1".
  16. Script error: No such module "Citation/CS1".
  17. Script error: No such module "Citation/CS1".
  18. 19.0 19.1 Script error: No such module "Citation/CS1".
  19. Script error: No such module "Citation/CS1".
  20. Script error: No such module "Citation/CS1".
  21. 22.0 22.1 Script error: No such module "Citation/CS1".
  22. 23.0 23.1 Script error: No such module "Citation/CS1".
  23. Script error: No such module "Citation/CS1".
  24. Kun Jia et al., Anti-neurofascin-155 antibody-positive neuromyelitis optica spectrum disorders, Journal of Neurological Sciences, January 16, 2019, DOI: https://doi.org/10.1016/j.jns.2019.01.024
  25. Script error: No such module "Citation/CS1".
  26. 27.0 27.1 Script error: No such module "Citation/CS1".
  27. Script error: No such module "Citation/CS1".
  28. 29.0 29.1 Script error: No such module "Citation/CS1".
  29. Script error: No such module "Citation/CS1".
  30. 31.0 31.1 31.2 /*-------------------------< P R O T E C T I O N I C O N >-------------------- the following line controls the page-protection icon in the upper right corner it must remain within this comment Lua error in Module:Effective_protection_level at line 60: attempt to index field 'TitleBlacklist' (a nil value).
    • /
    /*-------------------------< O V E R R I D E S >-------------------------------- cs1|2 references are wrapped in ... tags. Some wikis have not chosen to override the generic user agent italic styling as en.wiki has. This (untested) styling should override the user agent default when cs1|2 templates are rendered. Similarly, some languages use different quotation punctuation so that setting is also made available here.
    • /
    cite.citation { /* Reset italic styling set by user agent (only for cs1|2 templates; the reason for the .citation qualifier) */ font-style: inherit; } .citation q { /* Straight quote marks for ; keep same as MediaWiki:Common.css */ quotes: '"' '"' "'" "'"; } /* ID and URL access Both core and Common.css have selector .mw-parser-output a[href$=".pdf"].external for PDF pages. All TemplateStyles pages are hoisted to .mw-parser-output. We need to have specificity equal to a[href$=".pdf"].external for locks to override PDF icon.
    • /
    .citation .cs1-lock-free a { background: url(//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png) no-repeat; background-position: right .1em center; } .citation .cs1-lock-limited a, .citation .cs1-lock-registration a { background: url(//upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png) no-repeat; background-position: right .1em center; } .citation .cs1-lock-subscription a { background: url(//upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png) no-repeat; background-position: right .1em center; } .cs1-subscription, .cs1-registration { color: #555; } .cs1-subscription span, .cs1-registration span { border-bottom: 1px dotted; cursor: help; } /* Wikisource icon Experiment to see if it is possible/practical to add support for a wikisource icon when |chapter= or |title= is wikilinked to a source in wikisource ala cite wikisource
    • /
    .cs1-ws-icon a { background: url(//upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png) no-repeat; background-position: right .1em center; } /* Errors and maintenance */ code.cs1-code { /* ... style override: mediawiki's css definition is specified here: https://git.wikimedia.org/blob/mediawiki%2Fcore.git/69cd73811f7aadd093050dbf20ed70ef0b42a713/skins%2Fcommon%2FcommonElements.css#L199 */ color: inherit; background: inherit; border: inherit; /* code editor doesn't like inherit with border? https://www.w3.org/wiki/CSS/Properties/border suggests that inherit is ok the actual spec says the code editor is correct: https://www.w3.org/TR/css-backgrounds-3/#borders */ padding: inherit; } .cs1-hidden-error { display: none; font-size: 100%; } .cs1-visible-error { font-size: 100%; } .cs1-maint { display: none; color: #33aa33; margin-left: 0.3em; } /* Small text size Set small text size in one place. 0.95 (here) * 0.9 (from references list) is ~0.85, which is the lower bound for size for accessibility. Old styling for this was just 0.85. We could write the rule so that when this template is inside references/reflist, only then does it multiply by 0.95; else multiply by 0.85 */ .cs1-subscription, .cs1-registration, .cs1-format { font-size: 95%; } /* kerning */ .cs1-kern-left, .cs1-kern-wl-left { padding-left: 0.2em; } .cs1-kern-right, .cs1-kern-wl-right { padding-right: 0.2em; }
  31. Script error: No such module "Citation/CS1".
  32. Script error: No such module "Citation/CS1".
  33. Script error: No such module "Citation/CS1".
  34. Script error: No such module "Citation/CS1".
  35. Script error: No such module "Citation/CS1".
  36. Script error: No such module "Citation/CS1".
  37. Script error: No such module "Citation/CS1".
  38. Script error: No such module "Citation/CS1".
  39. Script error: No such module "Citation/CS1".
  40. Script error: No such module "Citation/CS1".
  41. Script error: No such module "Citation/CS1".
  42. Script error: No such module "Citation/CS1".
  43. Script error: No such module "Citation/CS1".
  44. Script error: No such module "Citation/CS1".
  45. Script error: No such module "citation/CS1".
  46. Script error: No such module "Citation/CS1".
  47. Script error: No such module "Citation/CS1".
  48. Script error: No such module "Citation/CS1".
  49. Script error: No such module "Citation/CS1".
  50. Script error: No such module "Citation/CS1".
  51. Script error: No such module "Citation/CS1".
  52. Script error: No such module "Citation/CS1".
  53. Script error: No such module "Citation/CS1".
  54. Script error: No such module "Citation/CS1".
  55. Script error: No such module "Citation/CS1".
  56. 57.0 57.1 Script error: No such module "Citation/CS1".
  57. Script error: No such module "Citation/CS1".
  58. Script error: No such module "Citation/CS1".
  59. Script error: No such module "Citation/CS1".
  60. Script error: No such module "citation/CS1".
  61. Script error: No such module "Citation/CS1".
  62. Script error: No such module "Citation/CS1".
  63. Glial Fibrillary Acid Protein Immunoglobulin G (GFAP-IgG) Related Myelitis: Characterization and Comparison with Aquaporin-4-IgG Myelitis, Elia Sechi, P. Pearse Morris, Andrew McKeon, Sean Pittock, Shannon Hinson, Brian Weinshenker, Allen J. Aksamit, Evan A. Jolliffe, Anastasia Zekeridou, Dean Wingerchuk, Eoin P. Flanagan, Neurology Apr 2018, 90 (15 Supplement) S13.006
  64. Script error: No such module "Citation/CS1".

Portions of content adapted from Wikipedias article on Neuromyelitis optica licensed under GNU FDL.

External links

Classification
[[d:Lua error in Module:WikidataIB at line 2616: attempt to index field 'wikibase' (a nil value). |D]]
External resources

Template:Multiple sclerosis

  1. REDIRECT Template:CNS diseases of the nervous system The diseases hurt
W8MD weight loss logo

Ad. Tired of being overweight?. W8MD's insurance Weight loss program can HELP*

Quick links: Medicine Portal | Encyclopedia‏‎‏‎ | Gray's Anatomy‏‎ | Topics‏‎ |‏‎ Diseases‏‎ | Drugs | Wellness | Obesity‏‎ | Metabolic syndrome | Weight loss*
Disclaimer: The entire contents of WIKIMD.ORG are for informational purposes only and do not render medical advice or professional services. If you have a medical emergency, you should CALL 911 immediately! Given the nature of the wiki, the information provided may not be accurate, misleading and or incorrect. Use the information on this wiki at your own risk! See full Disclaimer.
Link to this page: <a href="http://www.wikimd.org/wiki/Neuromyelitis_optica">Neuromyelitis optica</a>

  • Individual results may vary for weight loss from our sponsors.